These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 22978334)

  • 1. Optimize administration protocol of capecitabine plus docetaxel combination in metastatic breast cancer patients.
    Frances N; Woloch C; Marouani H; Mercier C; Iliadis A
    Curr Top Med Chem; 2012; 12(15):1665-8. PubMed ID: 22978334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?
    Leonard R; O'Shaughnessy J; Vukelja S; Gorbounova V; Chan-Navarro CA; Maraninchi D; Barak-Wigler N; McKendrick JJ; Harker WG; Bexon AS; Twelves C
    Ann Oncol; 2006 Sep; 17(9):1379-85. PubMed ID: 16966367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer.
    Leonard R; Hennessy BT; Blum JL; O'Shaughnessy J
    Clin Breast Cancer; 2011 Dec; 11(6):349-56. PubMed ID: 21856245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
    Puglisi F; Cardellino GG; Crivellari D; Di Loreto C; Magri MD; Minisini AM; Mansutti M; Andreetta C; Russo S; Lombardi D; Perin T; Damante G; Veronesi A
    Ann Oncol; 2008 Sep; 19(9):1541-6. PubMed ID: 18441329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of docetaxel combined capecitabine on metastatic breast cancer].
    Wang XX; Zhou ZM; Yuan ZY; Zhang DS; Shi YX; Jiang WQ
    Ai Zheng; 2007 Apr; 26(4):407-10. PubMed ID: 17430662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer.
    Frances N; Claret L; Bruno R; Iliadis A
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1413-9. PubMed ID: 21476101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of capecitabine in first-line treatment for patients with metastatic breast cancer.
    Gelmon K; Chan A; Harbeck N
    Oncologist; 2006; 11 Suppl 1():42-51. PubMed ID: 16971739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Docetaxel and capecitabine combination chemotherapy for patients with anthracycline-resistant metastatic breast cancer].
    Li SF; Wang X; Wang C; He LH; Shi YH; Hao CF; Dong GL; Tong ZS
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):944-6. PubMed ID: 19174000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study.
    Twelves C; Trigo JM; Jones R; De Rosa F; Rakhit A; Fettner S; Wright T; Baselga J
    Eur J Cancer; 2008 Feb; 44(3):419-26. PubMed ID: 18249110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer.
    Lebowitz PF; Eng-Wong J; Swain SM; Berman A; Merino MJ; Chow CK; Venzon D; Zia F; Danforth D; Liu E; Zujewski J
    Clin Cancer Res; 2004 Oct; 10(20):6764-9. PubMed ID: 15501952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
    Michalaki V; Gennatas S; Gennatas K
    Anticancer Drugs; 2009 Mar; 20(3):204-7. PubMed ID: 19174694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combination of docetaxel and capecitabine for the treatment of anthracycline-resistant advanced breast carcinoma].
    Zhang JD; Shao ZY
    Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):787-9. PubMed ID: 19173816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment for anthracycline-pretreated metastatic breast cancer.
    O'Shaughnessy J; Twelves C; Aapro M
    Oncologist; 2002; 7 Suppl 6():4-12. PubMed ID: 12454314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer.
    Wagstaff AJ; Ibbotson T; Goa KL
    Drugs; 2003; 63(2):217-36. PubMed ID: 12515569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
    Michalaki V; Fotiou S; Gennatas S; Gennatas C
    Anticancer Res; 2010 Jul; 30(7):3051-4. PubMed ID: 20683054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer.
    Jones L; Hawkins N; Westwood M; Wright K; Richardson G; Riemsma R
    Health Technol Assess; 2004 Feb; 8(5):iii, xiii-xvi, 1-143. PubMed ID: 14960257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.
    Ernst T; Merx K; Gnad-Vogt U; Lukan N; Kripp M; Schultheis B; Hochhaus A; Hofheinz RD
    Br J Cancer; 2007 Dec; 97(11):1475-9. PubMed ID: 18000507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
    O'Shaughnessy J; Miles D; Vukelja S; Moiseyenko V; Ayoub JP; Cervantes G; Fumoleau P; Jones S; Lui WY; Mauriac L; Twelves C; Van Hazel G; Verma S; Leonard R
    J Clin Oncol; 2002 Jun; 20(12):2812-23. PubMed ID: 12065558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer.
    Buzdar AU; Xu B; Digumarti R; Goedhals L; Hu X; Semiglazov V; Cheporov S; Gotovkin E; Hoersch S; Rittweger K; Miles DW; O'Shaughnessy J; Tjulandin S;
    Ann Oncol; 2012 Mar; 23(3):589-597. PubMed ID: 21633047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer.
    Silva O; Lopes G; Morgenzstern D; Lobo C; Doliny P; Santos E; Abdullah S; Gautam U; Reis I; Welsh C; Slingerland J; Hurley J; Gluck S
    Clin Breast Cancer; 2008 Apr; 8(2):162-7. PubMed ID: 18621613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.